drug · small molecule
maralixibat chloride
Marketedupdated 6mo agoby $MIRM Mirum Pharmaceuticals, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.
targets
Ileal sodium/bile acid cotransporter
all catalysts(0)
nothing on the calendar yet
Trials studying maralixibat chloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 13, 2027
116 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (42)
- Oct 5, 2043formulationUS 12296050
- Oct 5, 2043formulationUS 12296050
- Oct 5, 2043formulationUS 12296050
- Oct 5, 2043formulationUS 12296050
- Feb 12, 2040method-of-use (U-4187)US 11229647
- Feb 12, 2040method-of-use (U-3290)US 11229647
- Feb 12, 2040method-of-use (U-4187)US 11229647
- Feb 12, 2040method-of-use (U-4187)US 11229647
- Feb 12, 2040method-of-use (U-4187)US 11229647
- Feb 12, 2040method-of-use (U-4187)US 11497745
- Feb 12, 2040method-of-use (U-4187)US 11497745
- Feb 12, 2040method-of-use (U-4187)US 11497745
- Feb 12, 2040method-of-use (U-3290)US 11497745
- Feb 12, 2040method-of-use (U-4187)US 11497745
- Feb 12, 2040method-of-use (U-3974)US 11918578
- Oct 26, 2032method-of-use (U-3973)US 10512657
- Oct 26, 2032method-of-use (U-4186)US 10512657
- Oct 26, 2032method-of-use (U-4186)US 10512657
- Oct 26, 2032method-of-use (U-4186)US 10512657
- Oct 26, 2032method-of-use (U-4186)US 10512657
- Oct 26, 2032method-of-use (U-3850)US 10512657
- Oct 26, 2032method-of-use (U-3850)US 11229661
- Oct 26, 2032method-of-use (U-4186)US 11229661
- Oct 26, 2032method-of-use (U-4186)US 11229661
- Oct 26, 2032method-of-use (U-4186)US 11229661
- Oct 26, 2032method-of-use (U-4186)US 11229661
- Oct 26, 2032method-of-use (U-3973)US 11229661
- Oct 26, 2032method-of-use (U-4187)US 11376251
- Oct 26, 2032method-of-use (U-4187)US 11376251
- Oct 26, 2032method-of-use (U-3974)US 11376251
- Oct 26, 2032method-of-use (U-4187)US 11376251
- Oct 26, 2032method-of-use (U-4187)US 11376251
- Oct 26, 2032method-of-use (U-3973)US 12350267
- Oct 26, 2032method-of-use (U-3973)US 12350267
- Oct 26, 2032method-of-use (U-3973)US 12350267
- Oct 26, 2032method-of-use (U-3973)US 12350267
- Oct 26, 2032method-of-use (U-3973)US 12350267
- May 26, 2031method-of-use (U-4187)US 112600534.5y
- May 26, 2031method-of-use (U-4187)US 112600534.5y
- May 26, 2031method-of-use (U-3290)US 112600534.5y
- May 26, 2031method-of-use (U-4187)US 112600534.5y
- May 26, 2031method-of-use (U-4187)US 112600534.5y
FDA exclusivities (19)
- Jul 24, 2031ODE-490Orphan Drug (7y)4.7y
- Mar 13, 2031ODE-471Orphan Drug (7y)4.3y
- Mar 13, 2031ODE*ODE*4.3y
- Mar 13, 2030ODE*ODE*3.3y
- Mar 13, 2030ODE-429Orphan Drug (7y)3.3y
- Sep 29, 2028ODE-379Orphan Drug (7y)1.9y
- Sep 29, 2028ODE*ODE*1.9y
- Mar 13, 2027I-938Indication (3y)116d
- Mar 13, 2027I-938Indication (3y)116d
- Mar 13, 2027I-938Indication (3y)116d
- Mar 13, 2027I-938Indication (3y)116d
- Mar 13, 2027I-938Indication (3y)116d
- Sep 29, 2026NCENew Chemical Entity (5y)
- Sep 29, 2026NCENew Chemical Entity (5y)
- Sep 29, 2026NCENew Chemical Entity (5y)
- Sep 29, 2026NCENew Chemical Entity (5y)
- Sep 29, 2026NCENew Chemical Entity (5y)
- Sep 29, 2026NCENew Chemical Entity (5y)
- Mar 13, 2026NPPNew Product (3y)
News(1)
- Mirum succeeds in rare liver disease trial; First Tracks delivers in celiacMirum Pharmaceuticals’ late-stage win in ultra-rare liver diseases: The company’s ileal bile acid transporter inhibitor Livmarli significantly reduced cholestatic pruritus versus placebo in patient…endpoints · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that